Amgen (AMGN) PT Raised to $280 at Jefferies
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 7/10/2026
- Wall St flat as SK Hynix's stellar debut limits losses in chip stocks
- Oil prices fall on hopes for smoother shipping in Strait of Hormuz
- The real reason Meta shares are surging has nothing to do with its new AI model
- Stifel lifts Shopify to Buy, sees agentic commerce as next growth catalyst
- Delta Air Lines stock climbs on earnings beat and strong guidance
- Key things to know ahead of SK Hynix’s blockbuster US listing
- Almonty Industries (ALM) PT Raised to $33 at DA Davidson
- S&P Downgrades Oracle To 'bbb-/A-3'; Outlook Stable
- Meta falls as massive AI infrastructure spending plans overshadow chip progress
- The real reason Meta shares are surging has nothing to do with its new AI model
Amgen (AMGN) PT Raised to $250 at Wells Fargo
February 9, 2022 6:36 AM ESTWells Fargo analyst Mohit Bansal raised the price target on Amgen (NASDAQ: AMGN) to $250.00 (from $210.00) while maintaining a Equal Weight rating.... More
Amgen (AMGN) PT Raised to $285 at Oppenheimer
February 9, 2022 4:53 AM ESTOppenheimer analyst Jay Olson raised the price target on Amgen (NASDAQ: AMGN) to $285.00 (from $272.00) while maintaining a Outperform rating.... More
Amgen (AMGN) PT Raised to $233 at Barclays
February 9, 2022 4:47 AM ESTBarclays analyst Carter Gould raised the price target on Amgen (NASDAQ: AMGN) to $233.00 (from $228.00) while maintaining a Equalweight rating.... More
Amgen (AMGN) PT Raised to $238 at Morgan Stanley
February 9, 2022 1:09 AM ESTMorgan Stanley analyst Matthew Harrison raised the price target on Amgen (NASDAQ: AMGN) to $238.00 (from $235.00) while maintaining a Equalweight rating.... More
Amgen to buy back $6 billion in shares this qtr, provides long-term profit forecast
February 8, 2022 10:48 AM ESTBy Deena Beasley and Leroy Leo
(Reuters) -Amgen Inc said on Tuesday it would buy back up to $6 billion of its shares in the first quarter and forecast profit to more than double by 2030 on strong sales of its oncology drugs, biosimilars and other important products.
Shares of the U.S. biotechnology company jumped 8% to $241.37.
Amgen also said it expects to deliver mid-single-digit revenue growth through the end of the decade, driven by treatments such as cholesterol drug Repatha, psoriasis medicine Otezla and a pipeline of innovative products in development.
... MoreAmgen (AMGN) Outlines Growth Strategy Through 2030
February 8, 2022 10:22 AM ESTAmgen (NASDAQ: AMGN) today outlined its growth strategy through 2030, a period during which the Company expects to deliver attractive financial performance by serving many more patients globally than it does today, both with its current portfolio of marketed medicines and with the numerous new medicines it is advancing through its pipeline.
"Our strategy of delivering innovative medicines to address significant areas of unmet need has served us well over the past decade and remains our North Star moving forward in this exciting era of transformation for our industry," said Robert A.... More
